Dr. Nikki Roebuck

Dr. Nikki Roebuck, PhD: Senior Scientific Director (International, Oncology)

Dr. Nikki Roebuck is an experienced scientific leader with over 15 years of experience in Oncology Medical Affairs, including more than a decade dedicated to women’s cancers. She currently serves as Senior Scientific Director Oncology at AbbVie (International), where she leads medical strategy in ovarian cancer with a focus on advancing therapeutic innovation in platinum-resistant disease.

She holds a PhD in Biochemistry from the University of Manchester, awarded by the Wellcome Trust for her research in cell-matrix biology, and a BSc (Hons) in Biochemistry, also from Manchester, which included a research placement at the renowned Daresbury Laboratories.

Her professional journey spans leadership roles at TESARO, GSK, and ImmunoGen, where she contributed significantly to the launch and uptake of major therapies across gynecological malignancies. These include therapeutic advances in recurrent and first-line ovarian cancer, endometrial cancer, and platinum-resistant ovarian cancer. Her contributions span reimbursement negotiations, early access implementation, and policy engagement to support the introduction of novel treatments into real-world care pathways.

Dr. Roebuck has led regional and cross-functional medical teams across Europe, participated in scientific advisory group hearings at the European level, and supported clinical strategies and access discussions across multiple national markets. Known for her ability to bridge scientific insight with health system implementation, Dr. Roebuck remains committed to advancing equitable access to innovation in women's oncology.

She is a member of the European Society for Medical Oncology (ESMO) and has authored and presented research at leading international oncology and gynecology congresses.